NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $17.03 -1.03 (-5.70%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dyne Therapeutics Stock (NASDAQ:DYN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$16.96▼$18.1550-Day Range$17.31▼$26.7852-Week Range$11.92▼$27.31Volume2.01 million shsAverage Volume2.21 million shsMarket Capitalization$3.18 billionP/E RatioN/ADividend YieldN/APrice Target$32.17Consensus RatingModerate Buy Company Overview Dyne Therapeutics, Inc. is a biotechnology company focused on developing treatments for genetically driven muscle diseases. The company uses its FORCE platform, which is designed to deliver oligonucleotide therapeutics to skeletal muscle and other tissues by combining muscle-targeting antibodies with genetic medicines. Dyne’s research and development programs are aimed at conditions in which the underlying genetic mutations impair muscle function. Its pipeline has included DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping. These investigational therapies are intended to address disease-causing genetic mechanisms and improve the delivery of treatment to muscle cells. Founded in 2018 and headquartered in Waltham, Massachusetts, Dyne conducts research and clinical development activities intended to support patients with rare muscle diseases in the United States and other markets. The company is led by President and Chief Executive Officer John Wagner.AI Generated. May Contain Errors. Read More Dyne Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreDYN MarketRank™: Dyne Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 375th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 2 strong buy ratings, 11 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialDyne Therapeutics has a consensus price target of $32.17, representing about 87.8% upside from its current price of $17.13.Amount of Analyst CoverageDyne Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.59) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.30% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 13.54, which indicates bearish sentiment.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 3.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentDyne Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Dyne Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 5 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows3 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $99,697,629.00 in company stock.Percentage Held by Insiders9.46% of the stock of Dyne Therapeutics is held by insiders.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DYN Stock News HeadlinesDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 17 at 4:05 PM | globenewswire.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 16 at 2:28 AM | americanbankingnews.comMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage.September 18 at 1:00 AM | Crypto 101 Media (Ad)Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)September 11, 2026 | theglobeandmail.comRoyal Bank Of Canada Issues Pessimistic Forecast for Dyne Therapeutics (NASDAQ:DYN) Stock PriceSeptember 11, 2026 | americanbankingnews.comJohanna Friedl-Naderer Sells 900 Shares of Dyne Therapeutics (NASDAQ:DYN) StockSeptember 9, 2026 | insidertrades.comDyne Therapeutics (NASDAQ:DYN) Director Sells 426,412 SharesAugust 18, 2026 | insidertrades.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $19.56 at the start of the year. Since then, DYN shares have decreased by 12.4% and is now trading at $17.1280. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its quarterly earnings data on Thursday, July, 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.33. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $208 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 12,251,578 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional shareholders include BlackRock Inc. (6.64%), Jupiter Topco LLC (6.42%), Atlas Venture Life Science Advisors LLC (3.64%) and Bank of America Corp DE (1.20%). Insiders that own company stock include Venture Fund Xi LP Atlas, Jason P Rhodes, John Cox, Oxana Beskrovnaya, Douglas Kerr, Johanna Friedl-Naderer, Wildon Farwell, Susanna Gatti High, Richard William Scalzo, Erick Lucera, Dirk Kersten, Brian S Posner and Carlo Incerti. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings7/30/2026Today9/18/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DYN's financial health is in the Green zone, according to TradeSmith. DYN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees258Year Founded2018Price Target and Rating Average Price Target for Dyne Therapeutics$32.17 High Price Target$50.00 Low Price Target$10.00 Potential Upside/Downside+88.2%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$446.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.30% Return on Assets-50.33% Debt Debt-to-Equity Ratio0.28 Current Ratio12.02 Quick Ratio12.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.81 per share Price / Book2.51Miscellaneous Outstanding Shares186,746,000Free Float169,080,000Market Cap$3.19 billion OptionableOptionable Beta1.08 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DYN) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
